dexamethasone 21-(p-nitrophenyl carbonate) | 79360-11-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: dexamethasone 21-(p-nitrophenyl carbonate)
• 英文别名: [21-(4-nitrophenylformate)]dexamethasone；2-((8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl (4-nitrophenyl)carbonate；dexamethasone-21-(4'-nitrophenyl-carbonate)；[2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] (4-nitrophenyl) carbonate
• CAS: 79360-11-5
• 化学式: C₂₉H₃₂FNO₉
• 分子量: 557.573
• InChiKey: ATNAAFGYKQVZCC-XNXCGYEVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  40
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  156
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  dexamethasone 21-(p-nitrophenyl carbonate) 在 N-甲基吗啉 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 50.0h， 生成 [2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] N-[6-[4-(2,5-dioxopyrrol-1-yl)butanoylamino]hexyl]carbamate
  参考文献：
  名称：

  Synthesis of a dexamethasone-21-maleimido-linked derivative as a potential molecule for specific gene delivery

  摘要：

  The synthesis of the dexamethasone-21-maleimido-linked derivative 5 is described for the first time. The two principal steps of this synthesis are (1) the formation of a stable urethane 3 and (2) the introduction of a reactive maleimido group via a linker to get 5. This novel compound 5 is designed to examine the interaction of the steroid with other relevant molecules or functional groups, via the formation of conjugates. The structure of 5 was proven by NMR, taking advantage of a newly developed method (HMSC). (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(01)01291-6
• 作为产物：
  描述：

  二(对硝基苯)碳酸酯 、 地塞米松 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以400 mg的产率得到dexamethasone 21-(p-nitrophenyl carbonate)
  参考文献：
  名称：

  一种抗体偶联药物中间体及含有其的抗体偶联药物

  摘要：

  本发明公开了一种抗体偶联药物中间体及含有其的抗体偶联药物。该抗体偶联药物中间体具有如式(I)所示的抗体偶联药物中间体或其药学上可接受的盐：D‑La‑Lb‑M (I)；其中，D为糖皮质激素受体激动剂基团或大环内酯类免疫抑制剂基团；La为增加药物反应活性和亲水性的自裂解基团；Lb为酶催化裂解基团；M为带有马来酰亚胺结构的基团。本发明还提供了含有上述中间体的抗体偶联药物。本发明的中间体可有效提高药物分子的亲水性，与抗体结合形成抗体偶联药物能提高稳定性。

  公开号：

  CN115212315A

文献信息

• [EN] GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING GLUCOCORTICOID RECEPTOR ACTIVITY<br/>[FR] PEPTIDES DE LA SUPERFAMILLE DU GLUCAGON PRÉSENTANT UNE ACTION SUR LES RÉCEPTEURS AUX GLUCOCORTICOÏDES
  申请人：UNIV INDIANA RES & TECH CORP

  公开号：WO2013074910A1

  公开（公告）日：2013-05-23

  Provided herein are glucagon superfamily peptides conjugated with GR ligands that are capable of acting at a glucocorticoid receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.

  本文提供了与GR配体结合的葡萄糖素超家族肽，这些肽能够作用于糖皮质激素受体。本文还提供了该发明的结合物的药物组合物和工具包。此外，本文还提供了治疗疾病的方法，例如代谢紊乱，如糖尿病和肥胖，包括给予该发明的结合物。
• Conjugates of DNA interacting groups with steroid hormones for use as nucleic acid transfection agents
  申请人：Frey Felix

  公开号：US06753424B1

  公开（公告）日：2004-06-22

  The present invention relates to novel compounds comprising a steroid hormone linked to a DNA-interacting molecule that target nucleic acids to the cell nucleus. Further, the invention relates to a method for introducing nucleic acids into the nucleus of cells with the help of such compounds. Pharmaceutical preparations containing such compounds and the use of such compounds for gene therapy are also provided.

  本发明涉及一种新型化合物，该化合物包括一个类固醇激素与一个与DNA相互作用的分子相连，用于将核酸靶向细胞核。此外，该发明涉及一种利用这种化合物将核酸引入细胞核的方法。还提供了含有这种化合物的药物制剂以及利用这种化合物进行基因治疗的用途。
• Cell-specific glycopeptide ligands
  申请人：Merck & Co., Inc.

  公开号：EP0063373A1

  公开（公告）日：1982-10-27

  Cell-specific ligands comprising conjugates of saccharides and amino acids or peptides are synthesized from amino acids such as ornithine, lysine, peptides such as dilysine, diornithine or oligolysine and selected saccharides having reactive functional groups protected by appropriate blocking groups. Such glycopeptides include e.g. N2-N2, N6-bis[3-(a-D-mannopyranosylthio)propionyl]-L-lysyl} -N6- [3-(a-D-mannopyranosylthiolpropionyl]-L-lysine (5). Those compounds are useful as tissue specific substances, which when coupled with bioactive materials through metabolizable or hydrolyzable linkages, deliver such bioactive materials to the selected site. In this manner, antiinflammatory drugs such as dexamethasone are linked through a metabolizable or hydrolyzable linkage and on administration to an animal suffering from inflammatory disease carries the drug to the site of inflammation for intracellular release.

  由糖和氨基酸或肽的共轭物组成的细胞特异性配体是由氨基酸（如鸟氨酸、赖氨酸）、肽（如二赖氨酸、二鸟氨酸或低聚赖氨酸）和具有活性官能团并受适当阻断基团保护的精选糖合成的。这类糖肽包括如 N2-N2，N6-双[3-（a-D-吡喃甘露糖硫基）丙酰基]-L-赖氨酸}-N6-[3-（a-D-吡喃甘露糖硫基）丙酰基]-L-赖氨酸（5）。这些化合物是有用的组织特异性物质，当通过可代谢或可水解的连接与生物活性物质结合时，可将这些生物活性物质输送到选定的部位。通过这种方式，地塞米松等抗炎药物通过可代谢或可水解连接，在给患有炎症疾病的动物用药时，可将药物带到炎症部位进行细胞内释放。
• Cell-specific ligands for selective drug delivery to tissues and organs
  作者：Mitree M. Ponpipom、Robert L. Bugianesi、James C. Robbins、T. W. Doebber、T. Y. Shen

  DOI：10.1021/jm00144a004

  日期：1981.12

  Various numbers of D-mannose residues have been attached via spacer arms to lysine, dilysine, and oligolysine backbones. These D-mannosyl peptide analogues were found to be potent competitive inhibitors of the uptake of 125I-labeled D-mannose-bovine serum albumin conjugate by rat alveolar macrophages. The inhibitory potency of these synthetic ligands increased with increasing number of carbohydrate moieties. The chirality of the peptide backbone did not appear to play a major role in binding, whereas variations of the length and linkage of the spacer arm notably affected the inhibitory activities. The saccharide specificity of the macrophage receptor was demonstrated by the inactivity of the corresponding D-galactosyl peptide analogues. The L-fucosyl peptide derivative was only weakly active. The trimannosyldilysine ligand (KI = 3.9 microM) and its analogues are potentially useful in selective delivery of therapeutic agents to macrophages.
• WO2019209662A5
  申请人：——

  公开号：WO2019209662A5

  公开（公告）日：2022-04-14